LATUDA Drug Patent Profile

When do Latuda patents expire, and when can generic versions of Latuda launch?

Latuda is a drug marketed by Sunovion Pharms Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has forty-four patent family members in twenty-two countries.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the lurasidone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Latuda

A generic version of LATUDA was approved as lurasidone hydrochloride by ACCORD HLTHCARE on January 3^rd, 2019.

Summary for LATUDA

International Patents:	44
US Patents:	6
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATUDA

Paragraph IV (Patent) Challenges for LATUDA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LATUDA	Tablets	lurasidone hydrochloride	20 mg, 40 mg, 60 mg, 80 mg, and 120 mg	200603	14	2014-10-28

US Patents and Regulatory Information for LATUDA

LATUDA is protected by seven US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-004	Apr 26, 2012	AB	RX	Yes	No					Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-002	Oct 28, 2010	AB	RX	Yes	No					Y
Sunovion Pharms Inc	LATUDA	lurasidone hydrochloride	TABLET;ORAL	200603-004	Apr 26, 2012	AB	RX	Yes	No					Y

International Patents for LATUDA

When does loss-of-exclusivity occur for LATUDA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LATUDA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1884242
China	100422178
Russian Federation	2007148997	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ

Supplementary Protection Certificates for LATUDA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1884242	CA 2014 00049	Denmark		PRODUCT NAME: LURASIDON, EVENTUELT I FORM AF DEN FRIE BASE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER LURASIDONHYDROCHLORID; REG. NO/DATE: EU/1/14/913/001-021 20140321
1884242	PA2014034,C1884242	Lithuania		PRODUCT NAME: LURASIDONUM; REGISTRATION NO/DATE: EU/1/14/913 20140321
1884242	251 5024-2014	Slovakia		PRODUCT NAME: LURASIDON; REGISTRATION NO/DATE: EU/14/913/001 - EU/14/913/021 20140327

LATUDA (lurasidone) Investment Scenario and Fundamentals Analysis

Last updated: April 23, 2026

What is LATUDA and where does it sit in the branded antipsychotic market?

LATUDA is lurasidone, an oral atypical (second-generation) antipsychotic marketed by Sunovion Pharmaceuticals and co-promoted with AbbVie in the US. It is approved for:

• Schizophrenia (adults and adolescents, per US labeling)
• Bipolar depression (bipolar I depression, with dosing and indication-specific language)

Across major markets, lurasidone competes in a crowded atypical space that includes quetiapine, olanzapine, aripiprazole, risperidone/paliperidone, cariprazine, and ziprasidone. LATUDA’s commercial profile historically has depended on:

• Uptake in schizophrenia with a differentiated tolerability narrative versus more metabolically heavy agents
• Use in bipolar depression where efficacy and tolerability positioning matter
• Brand durability in the face of patent expiry and generic entry in key geographies (timing varies by market)

How has LATUDA’s revenue trajectory shaped its investment fundamentals?

LATUDA’s investor relevance is driven by two forces:

1. Generic pressure in markets where lurasidone patents have expired or where local market entry outpaces brand retention
2. Indication breadth and maintenance of clinical share through patient and prescriber familiarity, supported by label-driven dosing frameworks (notably adherence to food requirements)

From a fundamentals standpoint, the key commercial question is not whether lurasidone has clinical value (it does), but whether brand cash flows can persist long enough to offset:

• Pricing compression
• Share loss from generics
• Ongoing R&D costs and litigation costs (if any)
• Promotional intensity requirements to defend volume

What are the main IP and exclusivity risks impacting LATUDA cash flows?

LATUDA’s core investment risk is expiration and erosion of exclusivity. The practical impact is:

• Post-expiry, generic lurasidone availability reduces the brand’s ability to sustain premium pricing
• Even where exclusivity remains on paper, launch timing of authorized generics, biosimilar-like dynamics are not applicable here, but competitive entry accelerates volume loss

The patent stack that has underpinned LATUDA’s long-term protection has to be assessed at the level that matters for funding:

• Primary composition-of-matter term and any supplemental protection certificates (where applicable)
• Method-of-use patents that can delay generic filing or launch
• Formulation and dosing regimen patents that can complicate “easy” entry by generic manufacturers

For investment modeling, the critical variable is the remaining exclusivity runway by geography and whether any late-life patents meaningfully extend market exclusivity for lurasidone’s specific labeled uses.

What regulatory and labeling fundamentals drive sustained demand?

LATUDA’s commercial usability is strongly influenced by labeling requirements that shape adherence and prescriber workflow:

• Administration with food (dose-dependent) affects real-world adherence
• Dosing flexibility within labeled regimens affects titration decisions
• Safety and tolerability profile influences switching behavior away from alternatives (metabolic vs sedation vs EPS trade-offs)

From an investment underwriting lens, the most important labeling driver is whether LATUDA maintains a niche where prescribers prefer it over generics and over competing branded atypicals for:

• Patients with adherence patterns consistent with food requirements
• Patients who have failed other atypicals and where prescriber confidence remains high

Where does LATUDA’s clinical positioning matter most for payer and formulary decisions?

Payer acceptance tends to follow a predictable logic in atypical antipsychotics:

• Preferred formulary placement depends on negotiated pricing and evidence-based comparative value
• If generics are available, branded LATUDA often shifts to:
  • prior authorization
  • step edits
  • quantity limits
  • restricted status for specific subpopulations

LATUDA’s investment case improves if it maintains payer differentiation through:

• Lower switching rates due to tolerability
• Demonstrated improvement in bipolar depression endpoints (where relevant to plan populations)
• Evidence-backed patient persistence in schizophrenia

What are the competitive dynamics and how do they affect LATUDA’s price-volume economics?

The antipsychotic market is structurally competitive:

• Generic entry typically compresses net price quickly
• Broker and PBM formularies push toward least-cost options once interchangeability is established
• Brand survival depends on incremental niche performance and negotiated contracting

For LATUDA, the main economics after generic entry typically degrade along the lines of:

• Net sales decline driven by volume loss and price compression
• Marketing spend elasticity increases (defending share costs more as the brand loses natural premium)
• Any residual brand premium is usually contingent on payer pathways and “medical necessity” exceptions

What does the valuation-relevant picture look like across a typical scenario set?

Below are scenario frameworks that map to how branded antipsychotics behave after generic erosion. The exact quantitative values depend on company-level reporting and market-specific generic timelines; the underwriting logic is the same.

Scenario A: Base case (steady decline, moderate formulary restrictions)

• Net sales decline continues at a controlled rate
• LATUDA remains available under managed access rules
• Persistent use in a stable patient cohort offsets some generic pressure
• Margin holds if the company controls marketing spend and reduces commercial inefficiencies

Scenario B: Downside (faster volume loss, deeper payer restrictions)

• Additional generic entrants or aggressive pricing by generics
• More restrictive prior authorization and step edits
• Rising sales force cost per incremental prescription
• Margin compression due to higher promotional needs relative to ROI

Scenario C: Upside (contracting rebound, niche expansion)

• Strong contracting outcomes that preserve net price longer
• Higher persistence in bipolar depression populations with favorable outcomes
• Lower than expected payer restrictions due to negotiated value narratives

How should investors interpret LATUDA’s fundamentals vs. alternative atypicals?

LATUDA’s differentiator has been tolerability and clinical fit in specific patient profiles. In underwriting terms, compare it against:

• Quetiapine: strong bipolar and schizophrenia presence, but sedation/metabolic concerns can drive switching
• Aripiprazole: partial agonism, sometimes easier weight/sedation profile trade-offs
• Cariprazine: strong positioning in bipolar depression and negative symptoms for schizophrenia; can pull share from lurasidone where prescribers seek similar target-domain benefits
• Olanzapine: effective but often penalized in payer access due to metabolic risk

LATUDA’s investment relevance strengthens if it avoids “substitution drift” to the dominant class leaders in the plan formularies that already have deep generic competition or strong branded contracting.

What investment catalysts or watch-items matter for LATUDA?

For a branded atypical with generic pressure, catalysts tend to be incremental rather than transformative. The practical watch-list:

• Patent and exclusivity events (any granted method-of-use or formulation protections)
• Court decisions or settlement terms that can affect generic launch timing
• Label expansions (if any), but only if they change formulary dynamics or increase target population size
• Contracting outcomes with PBMs and major health plans
• Evidence updates that change prescribing behavior in bipolar depression or schizophrenia subsegments

What does the patent landscape imply for downside risk management?

Patent-driven risk management in LATUDA is less about avoiding generic entry entirely and more about:

• Timing of erosion by geography
• Whether generic launch occurs “cleanly” or faces delayed entries
• The durability of any brand-preferred positioning if “hard switching” occurs at launch

From a business perspective, the main downside risk is a step-function decline when a large generic competitor enters or when restrictive payer rules tighten around the exact dosing/indication.

LATUDA: Key business-relevant facts for investment modeling

Item	Investment relevance	What to track
Indications	Determines TAM and payer eligibility	Schizophrenia and bipolar depression persistence
Food requirement in dosing	Drives adherence and switching	Real-world persistence and refill patterns
Generic entry risk	Drives net price and volume erosion	Launch timing by geography
Formulary status	Determines access and prescription share	Step edits, prior authorization, PA criteria
Contracting with PBMs	Can soften price erosion	Net price vs list price trends

Key Takeaways

• LATUDA’s investment fundamentals are dominated by generic erosion timing and managed access dynamics rather than by near-term clinical novelty.
• The strongest underwriting drivers are payer behavior (formulary status, PA and step therapy) and patient persistence influenced by labeling usability, including the food administration requirement.
• The patent stack matters primarily for delay and geography, not for preventing competition indefinitely in an antipsychotic category.
• Competitive substitution risk is real because the atypical market has broad coverage from multiple classes; LATUDA must retain a niche through tolerability and outcomes in labeled populations.

FAQs

1) Is LATUDA’s investment profile more driven by sales execution or IP?

IP and exclusivity timing determine the slope of decline post-entry; sales execution and contracting determine how quickly the slope steepens under managed access.

2) What is the biggest fundamental threat to LATUDA revenue?

Generic lurasidone availability and resulting formulary substitution.

3) Which LATUDA factors most affect adherence and persistence?

Food-dependent dosing requirements and the resulting real-world adherence profile.

4) How should investors compare LATUDA against competing atypicals?

Use payer-driven economics and patient persistence metrics, not just clinical efficacy headlines.

5) What is the most useful indicator for future net sales direction?

The pace of formulary restriction tightening and net price erosion versus list price over consecutive reporting periods.

---

References

[1] U.S. Food and Drug Administration. “LATUDA (lurasidone) Prescribing Information.” FDA label documents.
[2] Sunovion Pharmaceuticals. LATUDA product information and US prescribing materials (as referenced in FDA label content).
[3] AbbVie (US). Public materials and co-promotion references related to LATUDA (as referenced in public company disclosures).